scholarly journals Venous Thrombosis could be Gender Specific, Women Beware!

2019 ◽  
Vol 69 (5) ◽  
pp. 503-509
Author(s):  
Swati Srivastava ◽  
Iti Garg ◽  
Lilly Ganju ◽  
Bhuvnesh Kumar

Venous thrombosis (VT) is the third major cause of mortality in the world after heart attack and stroke. Its two major clinical manifestations are deep vein thrombosis (DVT) and pulmonary embolism (PE) which are serious medical conditions but often remain under-diagnosed. Although rate of occurrence of venous thrombosis in men is slightly higher, a number of studies have pointed out that woman poses higher risk of venous thromboembolism (VTE) compared to men at various stages of life. Risk of VTE increases in women’s life particularly with use of oral contraceptives, during pregnancy and with exogenous administration of hormones like in post-menopausal hormone therapy. Various reports show that these factors increase risk of DVT and PE by several folds. DVT is considered as an important cause of maternal death in western countries. It is often asymptomatic and its signs and symptoms are similar to those of normal pregnancy. The hormonal changes at various stages of life and less physical activity increase the risk of VTE by blood flow stasis. It is extremely important for women to know the stages of life when they are prone to develop VTE, about its prevention and treatment. Detailed studies on differences in clinical manifestations of VTE between men and women are lacking. This review focusses on assessing the increased risk of VTE and its prognosis in women based on available literature.

2018 ◽  
Vol 5 (4) ◽  
pp. 51-55
Author(s):  
Vinícius Barros Prehl ◽  
Gabriel Leal Costa Moura ◽  
Fellipe Camargo Ferreira Dias ◽  
Roniel Thalles Almeida da Silva Rosa ◽  
Antônio Fagundes da Costa Júnior

Introdução: A gestação e o período pós-parto estão associados a diversas alterações fisiológicas que resultam na elevação do risco de eventos tromboembólicos. O tromboembolismo venoso (TEV) representa uma importante causa de morbimortalidade materna e se apresenta por meio de duas entidades clínicas diferentes: embolia pulmonar (EP) e trombose venosa profunda (TVP). A manifestação de sinais e sintomas comuns durante a gravidez associada à limitação do uso de radiação e elevação progressiva normal do D-dímero tornam o diagnóstico da TVP na gestação um desafio. Desenvolvimento: Trata-se de um artigo de revisão a partir de trabalhos selecionados sistematicamente nas bases de dados MEDLINE e LILACS com base nos indexadores: trombose venosa, gravidez e diagnóstico. Considerações finais: A gestação representa um estado pró-trombótico transitório, onde todos os componentes da tríade de Virchow são afetados. Diversos fatores associados ao período gestacional resultam em um padrão epidemiológico e de manifestação clínica distinto da população não gestante. A TVP representa a maioria dos casos de TEV sintomáticos no período pré-parto e acomete predominantemente o sistema venoso proximal. O estado pró-trombótico resulta na elevação dos níveis de D-dímero na gravidez, diminuindo a especificidade do exame. A ultrassonografia compressiva representa o exame de escolha diante da suspeita de TVP na gestação. A investigação diagnóstica possui limitações importantes e necessita de estudos direcionados para o desenvolvimento e aperfeiçoamento de estratégias para o diagnóstico de TVP em gestante.   Palavras-chave: Trombose Venosa; Gravidez; Diagnóstico. ABSTRACT Introduction: Gestation and the postpartum period are associated with several physiological changes that result in an increased risk of thromboembolic events. Venous thromboembolism (VTE) is an important cause of maternal morbidity and mortality and is presented through two different clinical entities: pulmonary embolism (PE) and deep vein thrombosis (DVT). The manifestation of common signs and symptoms during pregnancy associated with limitation in the use of radiatiotn and normal progressive elevation of D-dimer make the diagnosis of DVT during pregnancy challenging. Development: This is a review article based on systematically selected papers in the MEDLINE and LILACS databases based on the indexes: venous thrombosis, pregnancy and diagnosis. Final considerations: Gestation represents a transient prothrombotic state, where all components of the Virchow triad are affected. Several factors associated with the gestational period result in an epidemiological pattern and distinct clinical manifestation of the non-pregnant population. DVT represents the majority of cases of symptomatic VTE in the prepartum period and predominantly affects the proximal venous system. The prothrombotic state results in elevation of D-dimer levels in pregnancy, decreasing the specificity of the test. Compression ultrasonography represents the examination of choice in view of the suspicion of DVT during pregnancy. The diagnostic investigation has important limitations and needs studies directed to the development and improvement of strategies for the diagnosis of DVT in pregnant women. Keywords: Venous Thrombosis; Pregnancy; Diagnosis.


2016 ◽  
Vol 10 (3) ◽  
pp. 640-645 ◽  
Author(s):  
Mônica Souza de Miranda Henriques ◽  
Alexandre Rolim da Paz ◽  
Ana Beatriz Person Gaertner ◽  
Cibelle Ingrid Stephen Melo ◽  
Priscyanne Lins Filgueiras ◽  
...  

Introduction: Wipple disease (WD) is a rare chronic disease caused by the bacillus Tropheryma whipplei. Constitutive, rheumatologic, gastrointestinal, cardiac, cerebral, lymphatic, cutaneous, and ophthalmological signs are possible systemic symptoms. However, thrombotic manifestations are rarely described as “stroke-like syndrome” or arterial thrombosis. Diagnosis is based on clinical manifestations and pathological examination. Laboratory findings may include anemia, leukocytosis, and thrombocytosis. Objective: We report a case of venous thrombosis as initial manifestation of WD. Case Report: We describe the case of a 53-year-old male with iliofemoral vein thrombosis followed by intermittent diarrhea, loss of appetite, abdominal distension, and bloating. A mild malnutrition state with a weight loss of 13 kg, pallor (+/4 +), presence of lower-limb edema (+/4 +), and hypertympanic distended abdomen occurred. Laboratory tests on admission revealed anemia, positive inflammatory activity tests, and normal coagulation. Endoscopic examination showed villous edema with white dotted infiltrates in the second duodenal portion and intestinal lymphangiectasia in the terminal ileum. Pathological examination revealed numerous macrophages with positive periodic acid-Schiff inclusions. Venous Doppler ultrasound showed extensive deep thrombosis on the left lower limb and recanalization of the femoral vein in the right lower limb. The patient was treated with ceftriaxone and enoxaparin sodium, which led to an improvement of gastrointestinal and thrombosis symptoms. Comments: Hypercoagulability, endothelial damage, vasculitis, and blood stasis are present in T. whipplei infection, which are associated with the activation of inflammatory mechanisms as well as procoagulant and thromboembolic events. WD should be part of the differential diagnosis of diseases that cause venous thrombosis of unknown origin.


2021 ◽  
pp. 1-8
Author(s):  
Aviv Segev ◽  
Ehtesham Iqbal ◽  
Theresa A. McDonagh ◽  
Cecilia Casetta ◽  
Ebenezer Oloyede ◽  
...  

Background Clozapine is associated with increased risk of myocarditis. However, many common side-effects of clozapine overlap with the clinical manifestations of myocarditis. As a result, there is uncertainty about which signs, symptoms and investigations are important in distinguishing myocarditis from benign adverse effects of clozapine. Clarity on this issue is important, since missing a diagnosis of myocarditis or discontinuing clozapine unnecessarily may both have devastating consequences. Aims To examine the clinical characteristics of clozapine-induced myocarditis and to identify which signs and symptoms distinguish true myocarditis from other clozapine adverse effects. Method A retrospective analysis of the record database for 247 621 patients was performed. A natural language processing algorithm identified the instances of patients in which myocarditis was suspected. The anonymised case notes for the patients of each suspected instance were then manually examined, and those whose instances were ambiguous were referred for an independent assessment by up to three cardiologists. Patients with suspected instances were classified as having confirmed myocarditis, myocarditis ruled out or undetermined. Results Of 254 instances in 228 patients with suspected myocarditis, 11.4% (n = 29 instances) were confirmed as probable myocarditis. Troponin and C-reactive protein (CRP) had excellent diagnostic value (area under the curve 0.975 and 0.896, respectively), whereas tachycardia was of little diagnostic value. All confirmed instances occurred within 42 days of clozapine initiation. Conclusions Suspicion of myocarditis can lead to unnecessary discontinuation of clozapine. The ‘critical period’ for myocarditis emergence is the first 6 weeks, and clinical signs including tachycardia are of low specificity. Elevated CRP and troponin are the best markers for the need for further evaluation.


2015 ◽  
Vol 6 (03) ◽  
pp. 407-409 ◽  
Author(s):  
Josef Finsterer ◽  
Ernst Sehnal

ABSTRACTRecent data indicate that in patients with hereditary hemorrhagic teleangiectasia (HHT), low iron levels due to inadequate replacement after hemorrhagic iron losses are associated with elevated factor-VIII plasma levels and consecutively increased risk of venous thrombo-embolism. Here, we report a patient with HHT, low iron levels, elevated factor-VIII, and recurrent venous thrombo-embolism. A 64-year-old multimorbid Serbian gipsy was diagnosed with HHT at age 62 years. He had a history of recurrent epistaxis, teleangiectasias on the lips, renal and pulmonary arterio-venous malformations, and a family history positive for HHT. He had experienced recurrent venous thrombosis (mesenteric vein thrombosis, portal venous thrombosis, deep venous thrombosis), insufficiently treated with phenprocoumon during 16 months and gastro-intestinal bleeding. Blood tests revealed sideropenia and elevated plasma levels of coagulation factor-VIII. His history was positive for diabetes, arterial hypertension, hyperlipidemia, smoking, cerebral abscess, recurrent ischemic stroke, recurrent ileus, peripheral arterial occluding disease, polyneuropathy, mild renal insufficiency, and epilepsy. Following recent findings, hypercoagulability was attributed to the sideropenia-induced elevation of coagulation factor-VIII. In conclusion, HHT may be associated with hypercoagulability due to elevated factor-VIII associated with low serum iron levels from recurrent bleeding. Iron substitution may prevent HHT patients from hypercoagulability.


Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3669-3669 ◽  
Author(s):  
Anjali Sharathkumar ◽  
Elaine Southwood ◽  
Robert Fallon ◽  
Mark Heiny

Abstract Abstract 3669 Background: Post-thrombotic syndrome is increasingly diagnosed in children with VTE. Unlike adults, the clinical spectrum of PTS is not restricted to extremities but extends to non-extremity manifestations as well. In order to incorporate the entire spectrum of PTS in children, an expanded PTS assessment scale (EPTSAS) was developed based on critical evaluation of chronic consequences of extremity and non-extremity VTEs that could have been caused directly due to intravenous hypertension (Table 1). EPTSAS included signs and symptoms of PTS and divided them as major and minor criteria. Each component of scale was given a score of 0,1 or 2 based on its' presence/absence and the severity. Depending on the total score in both major and minor category, the severity of PTS was classified as “No PTS”, “PTS likely” and “PTS present” (A. Sharathkumar et al, Blood (ASH Annual Meeting Abstracts), 2007; 110: 3196). In a retrospective cohort of children with VTE, the sensitivity, specificity and inter-observer agreement for the diagnosis of PTS was 100%, 88.5% and 66% (interpreted as “good”) respectively (A. Sharathkumar, ISTH, SSC Subcommittee meeting, 2008). In present study, we evaluated the validity of EPTSAS prospectively. Patients/design: All the consecutive children (age<19 years) who were seen in hematology clinic at Riley Children's Hospital with a confirmed history of VTE and minimal follow up of 6 months were eligible to participate in the study. Clinical data about the patient demographics and VTE characteristics was collected. Severity of PTS was diagnosed using an established PTS assessment scale, “Kuhle's PTS scale”. Validity of EPTSAS was compared against Kuhle's scale. Two independent investigators assessed the severity of PTS using EPTSAS to evaluate an inter-observer agreement. Results: A total of 25 patients (26 VTE events) were enrolled in a study over a 15-month period (March 2009-June 2010). Median age of this cohort was 13.9 years (range: 3 days to 17 years), 9/25 (36%) children had known thrombophilic conditions. The locations of VTEs were as follows: extremity, 21/26; portal vein, 2/26; renal vein, 1/26; CNS, 1/27 and 1/26, isolated pulmonary embolism. Using Kuhle's classification 18/26(69%) children were diagnosed to have PTS (mild, 13/18; moderate, 5/18; severe, 0/26)(Table 1). Using EPTSAS, all the children with PTS received a score of >1, thus sensitivity of detecting PTS symptoms was 100%. Among 8 children with “no PTS”, only 6 received “0” score by EPTSAS, thus the specificity of EPTSAS was 75%. Inter-observer agreement was very good (kappa, 0.91) for reporting major symptoms and was fair in reporting symptoms of activity limitation and varicosities (kappa, 0.52 and 0.46 respectively) and was very good (kappa, 0.82) for reporting overall severity of PTS. Among 4 children with non-extremity PTS, 2 (1 renal and 1 portal vein thrombosis) were diagnosed to have “No” PTS and 2 (1, portal vein and 1, sinovenous thrombosis) were diagnosed to have “mild PTS” by Kuhle's classification. Using EPTSAS, 2 of these children (1, renal and 1, portal vein thrombosis) were diagnosed to have “PTS present” and remaining 2 were diagnosed as “PTS likely” implying higher sensitivity of EPTSAS. Conclusion: The findings of this cohort study suggest that EPTSAS is a valid tool to diagnose the clinical manifestations of PTS in children, specifically non-extremity manifestations. Our scale may need further refinement to improve the inter-observer agreement on the various components of the scale. Our finding needs to be confirmed in a larger cohort of study so that EPTAS can be used for evaluating outcome of children with VTE. Disclosures: No relevant conflicts of interest to declare.


2000 ◽  
Vol 83 (04) ◽  
pp. 577-582 ◽  
Author(s):  
Joan Guasch ◽  
Pieter Kamphuisen ◽  
Hans Vos ◽  
Frits Rosendaal ◽  
Rogier Bertina ◽  
...  

SummaryWe studied the HR2 haplotype of the factor V gene in a case-control study for venous thrombosis including 474 patients with a first deep-vein thrombosis and 474 age- and sex-matched healthy controls (Leiden Thrombophilia Study, LETS). We investigated both the original His1299Arg (A4070G) polymorphism and the Met385Thr (T1328C) polymorphism. This latter polymorphism, located in exon 8 (heavy chain), is always present in the HR2 haplotype, but also occurs on its own in a His1299 (wt) background. The HR2 haplotype was not associated with an increased risk of venous thrombosis (OR = 1.2, 95% confidence interval: 0.8-2.0). We did not find an association between the HR2 haplotype and a reduced sensitivity for activated protein C (APC) in non-carriers of factor V Leiden (FVL). However, in compound heterozygous FVL/HR2 carriers the sensitivity for APC was reduced. The HR2 haplotype was also associated with reduced factor V antigen levels in both patients and controls. Sequence analysis of the promoter region of factor V in HR2 homozygotes did not reveal any sequence variations that could explain the reduced FV levels. Our results show that the HR2 haplotype is not associated with an increased risk of venous thrombosis or with a reduced sensitivity for APC in non-FVL carriers. However, the HR2 haplotype is associated with a reduced sensitivity for APC in carriers of FVL and with reduced factor V antigen levels.


Blood ◽  
2011 ◽  
Vol 118 (15) ◽  
pp. 4239-4241 ◽  
Author(s):  
Kirsten van Langevelde ◽  
Willem M. Lijfering ◽  
Frits R. Rosendaal ◽  
Suzanne C. Cannegieter

Abstract Superficial vein thrombosis (SVT) is regarded a self-limiting disorder, although the authors of recent studies showed that ultrasonographically diagnosed SVT is a precursor for venous thrombosis. We aimed to determine whether the same holds true for clinically diagnosed SVT and to what extent it is associated with thrombophilia in a population-based case-control study (ie, Multiple Environmental and Genetic Assessment of risk factors for venous thrombosis). We found that a history of clinical SVT was associated with a 6.3-fold (95% confidence interval [CI] 5.0-8.0) increased risk of deep-vein thrombosis and a 3.9-fold (95% CI 3.0-5.1) increased risk of pulmonary embolism. Blood group non-O and factor V Leiden showed a small increase in SVT risk in controls, with odds ratios of 1.3 (95% CI 0.9-2.0) and 1.5 (95% CI 0.7-3.3), respectively. In conclusion, clinically diagnosed SVT was a risk factor for venous thrombosis. Given that thrombophilia was only weakly associated with SVT, it is likely that other factors (varicosis, obesity, stasis) also play a role in its etiology.


2016 ◽  
Vol 26 (6) ◽  
pp. 1044-1055 ◽  
Author(s):  
M. Cecilia Gonzalez Corcia ◽  
Carlo de Asmundis ◽  
Gian-Battista Chierchia ◽  
Pedro Brugada

AbstractBrugada syndrome is an inherited arrhythmogenic disorder, characterised by coved-type ST-segment elevation in the right precordial leads, and is associated with increased risk of sudden death. It is genetically and clinically heterogeneous, presenting typically in the fourth or fifth decade of life. The prevalence of Brugada syndrome in the paediatric population is low compared with the adult population. Interestingly, over the last several years, there has been growing evidence in the literature of onset of the disease during childhood. Most of the paediatric cases reported in the literature consist of asymptomatic Brugada syndrome; however, some patients manifest the disease at different regions of the cardiac conduction system at a young age. Early expression of the disease can be affected by multiple factors, including genetic substrate, hormonal changes, and still unknown environmental exposures. The initial manifestation of Brugada syndrome in children can include sinus node dysfunction and atrial arrhythmias. Brugada syndrome can also manifest as ventricular arrhythmias leading to sudden death at an early age. In symptomatic children, performance of the ajmaline test by an experienced team can be safely used as a diagnostic tool to unmask latent Brugada syndrome. Defining indications for an implantable cardioverter defibrillator in children with the diagnosis of Brugada syndrome remains challenging. Given the rarity of the syndrome in children, most paediatric cardiologists will only rarely see a young patient with Brugada syndrome and there is still no universal consensus regarding the optimal management approach. Care should be individualised according to the specific clinical presentation, taking into account the family history, genetic data, and the family’s specific preferences.


2010 ◽  
Vol 103 (06) ◽  
pp. 1136-1144 ◽  
Author(s):  
Valerio De Stefano ◽  
Ida Martinelli

SummaryVenous thrombosis typically involves the lower extremity circulation. Rarely, it can occur in the cerebral or splanchnic veins and these are the most frightening manifestations because of their high mortality rate. A third site of rare venous thrombosis is the deep system of the upper extremities that, as for the lower extremity, can be complicated by pulmonary embolism and post-thrombotic syndrome. The authors conducted a narrative review focused on clinical manifestations, risk factors, and treatment of rare venous thromboses. Local risk factors such as infections or cancer are frequent in thrombosis of cerebral or portal veins. Upper extremity deep-vein thrombosis is mostly due to local risk factors (catheter- or effort-related). Common systemic risk factors for rare venous thromboses are inherited thrombophilia and oral contraceptive use; chronic myeloproliferative neoplasms are closely associated with splanchnic vein thrombosis. In the acute phase rare venous thromboses should be treated conventionally with low-molecular-weight heparin. Use of local or systemic fibrinolysis should be considered in the case of clinical deterioration in spite of adequate anticoagulation. Anticoagulation with vitamin K-antagonists is recommended for 3–6 months after a first episode of rare venous thrombosis. Indefinite anticoagulation is recommended for Budd-Chiari syndrome, recurrent thrombosis or unprovoked thrombosis and permanent risk factors. In conclusion, the progresses made in the last couple of decades in diagnostic imaging and the broadened knowledge of thrombophilic abnormalities improved the recognition of rare venous thromboses and the understanding of pathogenic mechanisms. However, the recommendations for treatment mainly derive from observational studies.


2020 ◽  
pp. 112972982098320
Author(s):  
Karolina Chojnacka ◽  
Zbigniew Krasiński ◽  
Katarzyna Wróblewska-Seniuk ◽  
Jan Mazela

Introduction: Newborns treated in a neonatal intensive care unit (NICU) are susceptible to several complications one of them being vein thrombosis. Aim: The study aims to evaluate risk factors of catheter-related venous thrombosis, clinical manifestations, treatment, and the outcomes of thrombotic events (TE) during the neonatal period. Methods: This work is a case-control retrospective study performed on patients in the tertiary NICU between January 2013 and June 2016. The analysis includes data from infants with CVC diagnosed with thrombosis and infants with CVC, not being diagnosed with thrombosis (control group). Statistica 10 software was used for statistical analysis. Results: Vein thrombosis was diagnosed in 19 NICU infants including 16 cases of catheter-related vein thrombosis (84% of complicated cases). Other statistically significant risk factors were asphyxia, infection, and the duration of CVC use. The incidence of thrombosis in our population increased during the study which may result from a statistically significant increase in the number of inserted CVC (294 vs 435), and more frequent diagnosis of incidental thrombosis (1 vs 9). Conclusion: Vein catheterization, asphyxia, infection, and prolonged CVC use are critical risk factors for thrombosis in the neonatal period. Given the hereinbefore mentioned increased number of central line catheterizations in the NICU, it would be useful to conduct a prospective study with a scheduled routine ultrasound protocol applied not only as a tool to diagnose thrombosis but also to prevent it by determining a proper catheter for a particular vein.


Sign in / Sign up

Export Citation Format

Share Document